{"id":"nystatin-oral-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Oral irritation"}]},"_chembl":null,"_dailymed":{"setId":"4a670371-d373-1ba6-e063-6394a90a13b6","title":"NYSTATIN ORAL SUSPENSION (NYSTATIN) SUSPENSION [XTTRIUM LABORATORIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nystatin is a polyene macrolide antibiotic that selectively targets ergosterol, a sterol unique to fungal cell membranes. By binding to ergosterol, it disrupts membrane integrity and increases permeability, leading to loss of cellular contents and fungal cell death. It is not absorbed systemically when given orally, making it ideal for topical treatment of oral and gastrointestinal candidiasis.","oneSentence":"Nystatin binds to ergosterol in fungal cell membranes, creating pores that cause leakage and cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:06.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oral candidiasis (thrush)"},{"name":"Gastrointestinal candidiasis"},{"name":"Candida infections of the oral cavity and esophagus"}]},"trialDetails":[{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06637423","phase":"PHASE1, PHASE2","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":32},{"nctId":"NCT02389036","phase":"PHASE3","title":"Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-05-01","conditions":"Critical Illness, Sepsis, Septic Shock","enrollment":20010},{"nctId":"NCT04550546","phase":"PHASE1","title":"Effects of Nystatin Suspension Oral Application on Oral Microbial Community","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-05-15","conditions":"Dental Caries","enrollment":20},{"nctId":"NCT04837664","phase":"PHASE3","title":"Curcumin; Rose Bengal; Denture Stomatitis","status":"UNKNOWN","sponsor":"King Saud University","startDate":"2018-07-03","conditions":"Candida Albicans Infection, Cigarette Smoking","enrollment":45},{"nctId":"NCT00629122","phase":"PHASE4","title":"Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2008-02","conditions":"Kidney Failure, Chronic","enrollment":5},{"nctId":"NCT03320460","phase":"NA","title":"Photobiomodulation in Oral Lichen Planus","status":"UNKNOWN","sponsor":"University of Nove de Julho","startDate":"2018-11-01","conditions":"Lichen Planus, Oral, Low-Level Light Therapy","enrollment":44},{"nctId":"NCT03390374","phase":"PHASE4","title":"Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants","status":"COMPLETED","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2010-10","conditions":"Fungal Infections Systemic","enrollment":95},{"nctId":"NCT02208154","phase":"PHASE3","title":"Ecological Effects of Decolonisation Strategies in Intensive Care","status":"COMPLETED","sponsor":"MJM Bonten","startDate":"2013-12-01","conditions":"ICU-ecology (Multidrug Resistant Bacteria), ICU-acquired Bacteraemia","enrollment":8665},{"nctId":"NCT01718912","phase":"NA","title":"Periodontal Disease Treatment of a Physically Challenged Population","status":"COMPLETED","sponsor":"Oravital Inc","startDate":"2013-11","conditions":"Periodontal Disease","enrollment":11},{"nctId":"NCT02642900","phase":"PHASE4","title":"Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-07","conditions":"Photochemotherapy Reaction","enrollment":22},{"nctId":"NCT01427738","phase":"PHASE3","title":"Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-06","conditions":"HIV-1 Infection","enrollment":221},{"nctId":"NCT00814359","phase":"PHASE3","title":"Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis","status":"COMPLETED","sponsor":"Juravinski Cancer Centre Foundation","startDate":"2009-05","conditions":"Head and Neck Cancer, Mucositis","enrollment":67},{"nctId":"NCT01198223","phase":"PHASE2","title":"Effect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis","status":"COMPLETED","sponsor":"Qazvin University Of Medical Sciences","startDate":"2010-07","conditions":"Denture Stomatitis","enrollment":40},{"nctId":"NCT00942526","phase":"PHASE2","title":"Oral Anti-Infective Agent for Esophageal Anastomotic Leakage","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2009-06","conditions":"Anastomotic Leakage","enrollment":120},{"nctId":"NCT00659971","phase":"PHASE2","title":"Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis","status":"COMPLETED","sponsor":"Pacgen Biopharmaceuticals Corporation","startDate":"2008-01","conditions":"Oral Candidiasis","enrollment":223},{"nctId":"NCT00002112","phase":"NA","title":"Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"","conditions":"Candidiasis, Oral, HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"NAUSEA"},{"count":10,"reaction":"RASH"},{"count":8,"reaction":"ANAEMIA"},{"count":8,"reaction":"DIARRHOEA"},{"count":7,"reaction":"BURNING SENSATION"},{"count":7,"reaction":"DYSPNOEA"},{"count":5,"reaction":"FATIGUE"},{"count":5,"reaction":"HAEMOGLOBIN DECREASED"},{"count":5,"reaction":"HYPERTENSION"},{"count":5,"reaction":"MALAISE"}],"_approvalHistory":[{"date":"19940311","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"20020320","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"19960903","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"19940930","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"19920325","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"19890110","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"19841029","type":"ORIG","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"19970711","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"},{"date":"19941020","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA062512"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nystatin Swish and Swallow","Mycostatin"],"phase":"marketed","status":"active","brandName":"Nystatin oral suspension","genericName":"Nystatin oral suspension","companyName":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","companyId":"advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nystatin binds to ergosterol in fungal cell membranes, creating pores that cause leakage and cell death. Used for Oral candidiasis (thrush), Esophageal candidiasis, Intestinal candidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}